FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307554038> ?p ?o ?g. }

• W4307554038 endingPage "1121" @default.
• W4307554038 startingPage "1121" @default.
• W4307554038 abstract "Molds are ubiquitous in the environment, and immunocompromised patients are at substantial risk of morbidity and mortality due to their underlying disease and the resistance of pathogenic molds to currently recommended antifungal therapies. This combination of weakened-host defense, with limited antifungal treatment options, and the opportunism of environmental molds renders patients at risk and especially vulnerable to invasive mold infections such as Aspergillus and members of the Order Mucorales. Currently, available antifungal drugs such as azoles and echinocandins, as well as combinations of the same, offer some degree of efficacy in the prevention and treatment of invasive mold infections, but their use is often limited by drug resistance mechanisms, toxicity, drug-drug interactions, and the relative paucity of oral treatment options. Clearly, there is a need for agents that are of a new class that provides adequate tissue penetration, can be administered orally, and have broad-spectrum efficacy against fungal infections, including those caused by invasive mold organisms. Ibrexafungerp, an orally bioavailable glucan synthase inhibitor, is the first in a new class of triterpenoid antifungals and shares a similar target to the well-established echinocandins. Ibrexafungerp has a very favorable pharmacokinetic profile for the treatment of fungal infections with excellent tissue penetration in organs targeted by molds, such as the lungs, liver, and skin. Ibrexafungerp has demonstrated in vitro activity against Aspergillus spp. as well as efficacy in animal models of invasive aspergillosis and mucormycosis. Furthermore, ibrexafungerp is approved for use in the USA for the treatment of women with vulvovaginal candidiasis. Ibrexafungerp is currently being evaluated in clinical trials as monotherapy or in combination with other antifungals for treating invasive fungal infections caused by yeasts and molds. Thus, ibrexafungerp offers promise as a new addition to the clinician's armamentarium against these difficult-to-treat infections." @default.
• W4307554038 created "2022-11-03" @default.
• W4307554038 creator A5006450182 @default.
• W4307554038 creator A5025944964 @default.
• W4307554038 creator A5032603923 @default.
• W4307554038 creator A5046971149 @default.
• W4307554038 creator A5052134437 @default.
• W4307554038 creator A5060121384 @default.
• W4307554038 creator A5070632687 @default.
• W4307554038 creator A5071800632 @default.
• W4307554038 creator A5080865595 @default.
• W4307554038 creator A5089635085 @default.
• W4307554038 date "2022-10-25" @default.
• W4307554038 modified "2023-09-23" @default.
• W4307554038 title "Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections" @default.
• W4307554038 cites W2004503571 @default.
• W4307554038 cites W2016292914 @default.
• W4307554038 cites W2034556188 @default.
• W4307554038 cites W2039978475 @default.
• W4307554038 cites W2059625789 @default.
• W4307554038 cites W2065891345 @default.
• W4307554038 cites W2071436511 @default.
• W4307554038 cites W2121243320 @default.
• W4307554038 cites W2143691385 @default.
• W4307554038 cites W2161467702 @default.
• W4307554038 cites W2415563009 @default.
• W4307554038 cites W2480856538 @default.
• W4307554038 cites W2582680340 @default.
• W4307554038 cites W2595897956 @default.
• W4307554038 cites W2626950978 @default.
• W4307554038 cites W2756180633 @default.
• W4307554038 cites W2804930666 @default.
• W4307554038 cites W2809686644 @default.
• W4307554038 cites W2902361714 @default.
• W4307554038 cites W2962990120 @default.
• W4307554038 cites W3011590223 @default.
• W4307554038 cites W3017361294 @default.
• W4307554038 cites W3090150785 @default.
• W4307554038 cites W3122908468 @default.
• W4307554038 cites W3129541328 @default.
• W4307554038 cites W3137547661 @default.
• W4307554038 cites W3161375624 @default.
• W4307554038 cites W3164199071 @default.
• W4307554038 cites W3170623892 @default.
• W4307554038 cites W3176341989 @default.
• W4307554038 cites W3196992108 @default.
• W4307554038 cites W3202074216 @default.
• W4307554038 cites W3206023908 @default.
• W4307554038 cites W3207708343 @default.
• W4307554038 cites W4200371261 @default.
• W4307554038 cites W4205564523 @default.
• W4307554038 cites W4213443997 @default.
• W4307554038 cites W4220903290 @default.
• W4307554038 doi "https://doi.org/10.3390/jof8111121" @default.
• W4307554038 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36354888" @default.
• W4307554038 hasPublicationYear "2022" @default.
• W4307554038 type Work @default.
• W4307554038 citedByCount "8" @default.
• W4307554038 countsByYear W43075540382023 @default.
• W4307554038 crossrefType "journal-article" @default.
• W4307554038 hasAuthorship W4307554038A5006450182 @default.
• W4307554038 hasAuthorship W4307554038A5025944964 @default.
• W4307554038 hasAuthorship W4307554038A5032603923 @default.
• W4307554038 hasAuthorship W4307554038A5046971149 @default.
• W4307554038 hasAuthorship W4307554038A5052134437 @default.
• W4307554038 hasAuthorship W4307554038A5060121384 @default.
• W4307554038 hasAuthorship W4307554038A5070632687 @default.
• W4307554038 hasAuthorship W4307554038A5071800632 @default.
• W4307554038 hasAuthorship W4307554038A5080865595 @default.
• W4307554038 hasAuthorship W4307554038A5089635085 @default.
• W4307554038 hasBestOaLocation W43075540381 @default.
• W4307554038 hasConcept C142724271 @default.
• W4307554038 hasConcept C203014093 @default.
• W4307554038 hasConcept C2776391196 @default.
• W4307554038 hasConcept C2777292849 @default.
• W4307554038 hasConcept C2779175654 @default.
• W4307554038 hasConcept C2779320740 @default.
• W4307554038 hasConcept C2779548794 @default.
• W4307554038 hasConcept C2779629538 @default.
• W4307554038 hasConcept C2780035454 @default.
• W4307554038 hasConcept C2780402444 @default.
• W4307554038 hasConcept C2780651595 @default.
• W4307554038 hasConcept C2910751997 @default.
• W4307554038 hasConcept C2991737395 @default.
• W4307554038 hasConcept C71924100 @default.
• W4307554038 hasConcept C86803240 @default.
• W4307554038 hasConcept C89423630 @default.
• W4307554038 hasConcept C98274493 @default.
• W4307554038 hasConceptScore W4307554038C142724271 @default.
• W4307554038 hasConceptScore W4307554038C203014093 @default.
• W4307554038 hasConceptScore W4307554038C2776391196 @default.
• W4307554038 hasConceptScore W4307554038C2777292849 @default.
• W4307554038 hasConceptScore W4307554038C2779175654 @default.
• W4307554038 hasConceptScore W4307554038C2779320740 @default.
• W4307554038 hasConceptScore W4307554038C2779548794 @default.
• W4307554038 hasConceptScore W4307554038C2779629538 @default.
• W4307554038 hasConceptScore W4307554038C2780035454 @default.
• W4307554038 hasConceptScore W4307554038C2780402444 @default.

• next